Division PerformanceSales for three of the four divisions surpassed Street expectations, with significant momentum in Cardiac Pacing, Structural Heart, Neuromod, and Diabetes.
Financial PerformanceFirst-quarter revenue of $8.0 billion exceeded both consensus and internal estimates, showcasing strong financial performance.
Product MomentumMedtronic is in the early stages of several new product cycles such as PFA, TAVR, surgical robotics, and renal denervation, driving future growth potential.